ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 07:30 ET
|
ContraFect Corporation
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
June 17, 2020 07:30 ET
|
ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
June 15, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
May 26, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
May 21, 2020 22:59 ET
|
ContraFect Corporation
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
December 20, 2019 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Applied Silver Announces Formation of Athlete Advisory Council with the Appointment of Ian Williams, Former San Francisco 49ers Player, as Athletics Ambassador
March 13, 2019 07:00 ET
|
Applied Silver Inc.
HAYWARD, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Applied Silver, Inc. today announced the appointment of Ian Williams, former San Francisco 49ers defensive lineman and NBC Bay Area Sports Analyst...
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
February 07, 2019 09:18 ET
|
Vystar Corp
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria.Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other...
Vystar Debuts Enhanced RxAir® UV Light Air Purifiers to Fight Flu, Colds & Airborne Germs
January 28, 2019 09:37 ET
|
Vystar Corp
Features longer-lasting, more effective UV light for more efficient inactivation of viruses and bacteriaRxAir available for medical, business and residentialRxAir now available via Vystar’s medical...
ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference
March 14, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, New York, March 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...